Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2020
If successful, balixafortide will be the first in class CXCR4 antagonist approved for a solid tumor indication widening the opportunities in the field of immuno-oncology.